OCA at 10:28, 10 January 2024

OCA — Wed, 10 Jan 2024 10:28:06 GMT

←Older revision		Revision as of 10:28, 10 January 2024
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8txy is ~~ON HOLD until Paper~~ Publication	+	==X-ray crystal structure of JRD-SIK1/2i-3 bound to a MARK2-SIK2 chimera==
		+	<StructureSection load='8txy' size='340' side='right'caption='[[8txy]], [[Resolution\|resolution]] 2.10Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[8txy]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8TXY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8TXY FirstGlance]. <br>
		+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.1Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=SJ0:N-[(5P,8R)-5-(2-cyano-5-{[(3R)-1-methylpyrrolidin-3-yl]methoxy}pyridin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide'>SJ0</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8txy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8txy OCA], [https://pdbe.org/8txy PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8txy RCSB], [https://www.ebi.ac.uk/pdbsum/8txy PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8txy ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/MARK2_HUMAN MARK2_HUMAN]
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	The salt-inducible kinases (SIK) 1-3 are key regulators of pro- versus anti-inflammatory cytokine responses during innate immune activation. The lack of highly SIK-family or SIK isoform-selective inhibitors suitable for repeat, oral dosing has limited the study of the optimal SIK isoform selectivity profile for suppressing inflammation in vivo. To overcome this challenge, we devised a structure-based design strategy for developing potent SIK inhibitors that are highly selective against other kinases by engaging two differentiating features of the SIK catalytic site. This effort resulted in SIK1/2-selective probes that inhibit key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3) as detected with an internally generated phospho-Ser329-CRTC3-specific antibody. These inhibitors also suppress production of pro-inflammatory cytokines while inducing anti-inflammatory interleukin-10 in activated human and murine myeloid cells and in mice following a lipopolysaccharide challenge. Oral dosing of these compounds ameliorates disease in a murine colitis model. These findings define an approach to generate highly selective SIK1/2 inhibitors and establish that targeting these isoforms may be a useful strategy to suppress pathological inflammation.

-	~~Authors~~:	+	Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation.,Babbe H, Sundberg TB, Tichenor M, Seierstad M, Bacani G, Berstler J, Chai W, Chang L, Chung M, Coe K, Collins B, Finley M, Guletsky A, Lemke CT, Mak PA, Mathur A, Mercado-Marin EV, Metkar S, Raymond DD, Rives ML, Rizzolio M, Shaffer PL, Smith R, Smith J, Steele R, Steffens H, Suarez J, Tian G, Majewski N, Volak LP, Wei J, Desai PT, Ong LL, Koudriakova T, Goldberg SD, Hirst G, Kaushik VK, Ort T, Seth N, Graham DB, Plevy S, Venable JD, Xavier RJ, Towne JE Proc Natl Acad Sci U S A. 2024 Jan 2;121(1):e2307086120. doi: , 10.1073/pnas.2307086120. Epub 2023 Dec 26. PMID:38147543<ref>PMID:38147543</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased~~ Structures]]	+	</div>
		+	<div class="pdbe-citations 8txy" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Collins B]]
		+	[[Category: Lemke CT]]
		+	[[Category: Raymond DD]]
		+	[[Category: Seierstad M]]
		+	[[Category: Shaffer PL]]
		+	[[Category: Steele R]]

OCA at 10:56, 4 October 2023

OCA — Wed, 04 Oct 2023 10:56:21 GMT

←Older revision		Revision as of 10:56, 4 October 2023
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8txy is ON HOLD	+	The entry 8txy is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "8txy" [edit=sysop:move=sysop]

OCA — Wed, 30 Aug 2023 07:48:54 GMT

Protected "8txy" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:48, 30 August 2023

OCA: New page: '''Unreleased structure''' The entry 8txy is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 30 Aug 2023 07:48:53 GMT

New page: '''Unreleased structure''' The entry 8txy is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 8txy is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]

8txy - Revision history

OCA at 10:28, 10 January 2024

OCA at 10:56, 4 October 2023

OCA: Protected "8txy" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 8txy is ON HOLD Authors: Description: Category: Unreleased Structures